Login
Subscribe
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
clinical trials, business, drug development
Celladon Shutters Its R&D
Kerry Grens | Jun 26, 2015 | 1 min read
Biotech firm likely to pull the plug after its gene therapy product fails.